Future Clinical Practice Considerations with ASCENT-03

If sacituzumab govitecan (SG) is approved for first-line metastatic TNBC, it could meaningfully shift clinical practice by providing an effective option for patients ineligible for immunotherapy or with PD-L1–negative disease. Potential barriers include managing toxicities such as neutropenia and diarrhea, ensuring timely access through insurance coverage, and coordinating infusion logistics. Successful integration into practice will require close collaboration between pharmacists and physicians. Pharmacists play a key role in toxicity monitoring, patient education, and advocating for growth factor prophylaxis, while physicians tailor therapy selection and sequencing. Coordinated efforts in coverage, scheduling, and ongoing education will ensure safe, effective, and equitable delivery of SG in the evolving treatment landscape.